In conclusion, our preliminary results suggests that dalpiciclib may be a promising therapeutic strategy for patients with MM harboring CDK4 amplification and/or mutations in CDK4 pathway when applied as monotherapy or in combination with other therapeutic approaches. The gene discussed is CDK4; the disease is Miyoshi myopathy.